ACADEMIC BACKGROUND

Northside High School, Atlanta, Ga. 1970

Oglethorpe University, Atlanta, Ga. BS 1976

Research Fellowship, Anatomic Pathology, Medical College of Georgia 1978

Medical College of Georgia, Augusta, Ga. M.D. 1980

Internship and Residency in Internal Medicine MI Bassett Hospital, Cooperstown, NY 1980-83

Clinical Fellow in Medicine, Columbia University College of Physicians and Surgeons,    1980-83

Senior Associate, Department of Medicine, Emory University School of Medicine,  1983-86

Clinical Instructor of Medicine, Emory University School of Medicine, 1986 - present

Attending Physician in Internal Medicine, Atlanta Center for Medicine, 1986 - 97

Medical Director, Osteoporosis Center of Atlanta, 1988 - present

Medical Director, Atlanta Research Center, LLC 1989 - present

Attending Physician, DeKalb Internal Medicine, LLC 1997 - present

 

PROFESSIONAL ORGANIZATIONS

Certified by the American Board of Internal Medicine 1983

Fellow of the American College of Physicians 1993

Member of the American Society for Bone and Mineral Research since 1986

Member of the American Society of Internal Medicine since 1988

President of the Georgia Chapter of the National Osteoporosis Foundation, 1987-91

Member of the Scientific Advisory Board of the National Osteoporosis Foundation

Washington, DC 1989-1995

Education Committee, Scientific Advisory Board of the National Osteoporosis Foundation 1990-1995

Member of the Clinical Society for Bone Densitometry since 1993

Member OsNet Inc.: A Non-profit Clinical Research Network since 1995

Member of the Southeastern Regional Scientific Advisory Board of the Better Bones Alliance, Proctor and Gamble Pharmaceuticals and Aventis, 1998 - present

Member of the National Internal Medicine Advisory Board, Eli Lilly and Company 2001 - present

Member of the US Bazedoxifene Steering Committee, Wyeth Research, 2002 – present

 

HOSPITAL AFFILIATION

DeKalb Medical Center, Decatur, Georgia since 1986-present

CONTRACT RESEARCH EXPERIENCE

1985-1990

Coinvestgator

Protocol: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis PMOII

Sponsor:  Norwich Eaton Pharmaceuticals (Division of Proctor and Gamble)           

Drug: Etidronate disodium      

1990-1998

Principal Investigator

Protocol: A multi-centered, double-blind, placebo-controlled study to investigate the 

efficacy of salmon calcitonin nasal spray in the prevention of osteoporotic vertebral 

fractures, Miacalcin 320

Sponsor: Sandoz Pharmaceutical

Drug: Salmon calcitonin nasal spray

1992-1997

Principal Investigator

Protocol: A phase III study of intermittent cyclical tiludronate in the treatment os 

established post-menopausal osteoporosis, Tiludronate 004

Sponsor: Sanofi Winthrope

Drug: Tiludronate

1992-1996

Principal Investigator

Protocol: A phase III study of intermittent cyclical tiludronate in the treatment of post-menopausal women with low bone mineral mass and no vertebral fractures, Tiludronate 005

Sponsor: Sanofi Winthrope

Drug: Tiludronate

1993-1999

Principal Investigator

Protocol: A multicenter, randomized, double-blind, placebo-controlled parallel group   

study to determine the efficacy and safety of risedronate in the treatment of osteoporosis  in elderly women, RHN 9193

Sponsor: Proctor and Gamble Pharmaceuticals

Drug: Risedronate

1993-1995

Principal Investigator

Protocol: A randomized, double-blind, placebo-controlled, multicenter, parallel group study to determine the efficacy and safety of risedronate in the treatment of postmenopausal osteopenic women, RON 9393

Sponsor: Proctor and Gamble Pharmaceuticals

Drug: Risedronate

1995-1998

Principal Investigator

Protocol: A triple-blind, randomized, placebo-controlled, parallel-group multicenter       

study to evaluate the safety, tolerability and effect on bone mineral density of 10mg of alendronate sodium for the treatment of postmenopausal osteoporosis in elderly female long term care facility residents, FOS351

Sponsor: Merck Human Health

Drug: Alendronate Sodium

1996-2000

Principal Investigator

Protocol: Multi-center, double-blind, placebo-controlled, randomized study on the efficacy and safety of ibandronate during 3 years’ treatment in patients with postmenopausal osteoporosis and vertebral fractures using a continuous oral (2.5 mg daily) and an intermittent oral (20 mg every 2^nd day for 24 days every 3 months) dosing regimen, MF4411

Sponsor: Roche

Drug: Ibandronate

1997-1999

Principal Investigator

Protocol: A triple-blind, randomized, placebo-controlled multicenter study to compare efficacy of oral alendronate sodium to intranasal calcitonin-salmon for treatment of postmenopausal osteoporosis (IN-FOCAS), FOS417

Sponsor: Merck Human Health

Drug: Alendronate Sodium

1997-1999

Principal Investigator

Protocol: Safety and Efficacy of Buprenorphine TDS (Transdermal Delivery System) 12.5, 25. and 50ug/hr Applied every Seven Days for Sixty Days vs 5mg Oxycodone/325 mg acetomenophen Tablets q6h PRN vs Placebo in Patients with Chronic Back Pain, BP96-102

Sponsor: Purdue Pharma

Drug: Buprenorphine

1997-1999

Principal Investigator

Protocol: A Long-Term, Open-Label, Clinical Use Safety Study of Buprenorphine TDS (Transdermal Delivery System) 12.5, 25, and 50ug/hr Applied Every 72 hours for the Management of Ongoing Pain Syndromes, BP96-0103

Sponsor: Purdue Pharma

Drug: Buprenorphine

1998-1999

Principal Investigator

Sponsor: Purdue Pharma

Protocol: A Comparative Study of Buprenorphine TDS, Oxycodone/Acetomentophen Tablets QID and Placebo in Patients with Chronic Back Pain, BP96-0604

Drug: Buprenorphine

1998-2000

Principal Investigator

Sponsor: Pfizer

Protocol: Safety and efficacy of droloxifene for preventing bone loss in normal, early postmenopausal women, 174-113

Drug: droloxifene, raloxifene

1998-2000

Principal Investigator

Protocol: A Randomized, Double-Blind, Active - and Placebo Controlled, Parallel Group, Multicenter Study Assessing the Safety and Protective Effect on the Endometrium of 4 Dosage Combinations of Norethindrone Acetate Plus Ethinyl Estradiol, 376-401

Sponsor: Parke Davis

Drugs: Ethinyl Estradiol and Norethindrone1997-98

1998-2000

Principal Investigator

Protocol: A Double-Blind, Placebo Controlled Safety and Efficacy Trial with Transdermal Zolendronate (CGP 42446) in the Treatment of Postmenopausal Osteoporosis, 18

Sponsor: Novartis

Drug: Zolendronate

1998-99

Principal Investigator

Sponsor: Merck Human Health

Protocol: A randomized, placebo and active comparator-controlled, parallel group,   double blind study to compare the efficacy and safety of MK-0966 tablets vs. nabumetone tablets in patients with osteoarthritis of the knee,

Drug: rofecoxib and nabumetone

1999 – 2000

Principal Investigator

Sponsor: Bayer

Protocol: A multi-center, double blind, placebo controlled, group comparison study to investigate the efficacy, tolerability and safety of BAY 12,9566 as compared to placebo, in the treatment of patients with mild to moderate osteoarthritis of the knee, over 3 years, #100011

Drug:  BAY 12, 9566 (Metaloprotease inhibitor)

1999- 2002

Principal Investigator

Sponsor: Parke Davis – Pfizer

Protocol: Beyond endorsed lipid lowering with EBCT scanning, BELLES

Drug: atorvastatin and pravastatin

1999- 2001

Sub-investigator

Protocol: A 20-week open-label assessment of the safety and efficacy profile of atorvastatin when used to optimally control dyslipidemia in postmenopausal patents. 

Acronym: DUET( Atrovastatin Drug Utilization and Experience Trial)

Sponsor: Park Davis – Pfizer

Drug: atorvastatin

1999-2000

Principal Investigator

Protocol: Clinical Protocol for the Multicenter, Double-bind, Parallel Group Study Comparing the Effects on Renal Function and the Incidence of Gastrointestinal Ulcer Associated with Valdecoxib 20 mg and 40 mg with that of Naproxen 500 mg bid in Patients with Osteoarthritis or Rheumatoid Arthritis.

Sponsor: Searle

Drug: valdecoxib and naproxen sodium

1999-2000

Principal Investigator

Protocol: A double-blind, randomized placebo-controlled, multi-center study to evaluate upper gastrointestinal tolerability upon rechallange in postmenopausal women with osteoporosis who previously discontinued alendronate due to upper gastrointestinal symptoms.

Sponsor: Merck

Drug: alendronate

1999-2001

Principal Investigator

Protocol: A 12-week, randomized, partially-blinded, active and placebo controlled, parallel group, multi-center study assessing the effect of norethendrone acetate plus ethinyl estradiol on endothelial dysfunction in postmenopausal women.

Sponsor: Parke Davis

Drug: norethindrone, ethinyl estradiol, raloxifene

2000-2001

Principal Investigator

Protocol: A randomized placebo-controlled, parallel group, double blind study to evaluate the safety and efficacy of rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg n patients with osteoarthritis of the knee or hip.

Sponsor: Merck Research Laboratories

Drug: rofecoxib and celecoxib

2001-present

Principal Investigator

Protocol: A Multicenter, Double-Blind, Randomized, Placebo and Raloxifene-Controlled Study to Assess Safety and Efficacy of TSE-424 in the Prevention of Postmenopausal Osteoporosis, W300

Sponsor: Wyeth Research

Drug: Bazedoxifene Acetate/Raloxifene

2001-present

Principal Investigator

Protocol: Fracture Incidence Reduction and Safety of TSE-424 (Bazedoxifene Acetate) Compared to Placebo and Raloxifene in Osteoporotic Postmenopausal Women, W301

Sponsor: Wyeth Research

Drug: Bazedoxifene Acetate/Raloxifene

2001-present

Principal Investigator

Protocol: Protocol Title: Comparison of Raloxifene to Alendronate in Postmenopausal Women with Osteoporosis (H3S-US-GGKO) EVA

Sponsor: Eli Lilly and Company

Drug: Raloxifene and alendronate

2002-present

Principal Investigator

Protocol: A Double-Blind, Randomized, Placebo and Active Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations Postmenopausal Women, W303

Sponsor: Wyeth Research

Drug: Bazedoxifene Acetate and Premarin/Raloxifene

2002-present

Principal Investigator

Protocol: A Randomized, Double-Blind, Placebo-controlled, Multi-Dose Phase 2 Study to Determine the Efficacy, Safety, and Tolerability of AMG 162 in the Treatment of Postmenopausal Women with Low Bone Mineral Density.

Sponsor: Amgen

Drug: AMG 162 / alendronate

2002-present

Principal Investigator

Protocol: Multinational, multicenter, double-blind, randomized, placebo controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture.

Sponsor: Novartis

Drug: Zoledronic Acid

2003-present

Principal Investigator

Protocol: Forteo Observational Study, DANCE Study

Sponsor: Eli Lilly and Company

Drug: Teraparatide

2004-present

Principal Investigator

Protocol: Open-label study to determine how prior therapy with Alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teraparatide, OPTIMIZE Study.

Sponsor: Aventis

Drug: Teraparatide

2004-present

Principal Investigator

Protocol: Bone Histomorphometry, Microarchitecture and Matrix Structure in Patients Receiving Long-term Alendronate or Risedronate

Sponsor: Proctor and Gamble Pharmaceuticals

Drug: Risedronate and Alendronate

2004-present

Principal Investigator

Protocol: Effects of Arzoxifene on Vertebral Fracture Incidence and of Invasive Breast Cancer Incidence in Post Menopausal Women with Osteoporosis or Low Bone Density

Sponsor: Eli Lilly and Company

Drug: Arzoxifene

 

PUBLICATIONS

D. Hewitt, G. Woodson, L. L. Vacca A comparison of methods to  localize peroxidase activity in erythrocytes and immunoperoxidase procedures.  GA J Science, 1978;3:101.

L. L. Vacca, D. Hewitt, G. Woodson, A comparison of methods  using diaminobenzidine (DAB) to localize peroxidase in erythrocytes, neutrophils, and peroxidase-antiperoxidase complex. Stain Tech, 1978;53:331-336.

G. Woodson, Coherence therapy with phosphate and etidronate for osteoporosis: preliminary results. in Osteoporosis 1987, Proceedings of the Second International Symposium on Osteoporosis Aalborg, Denmark pp. 1188-1189

N. B. Watts, G. Woodson, S. O'Neal, B.D. Catherwood Serum bone Gamma-carboxyglutamate- containing protein (BGP) declines with time after menopause but does not correlate with age.  Abstract, Clinical Research, 1989;37.

G. Woodson, Coherence therapy increases bone mass.  Abstract,   J Bone Min Res 1989: Supp 1.

N. B. Watts, S. T. Harris, H. K. Genant, R. D. Wasnich, P. D.  Miller, R. D. Jackson, A. A. Licata, P. D. Ross, G. C. Woodson, M. J. Yanover, W. J. Mysiw, L. Kohse, M. B. Rao, P. Steiger, B. Richmond, C. H. Chestnut, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Eng J Med 1990;323;73-79.

G. Woodson, Etidronate combined with estrogen increases bone mass in osteopenia and osteoporosis.  in Osteoporosis 1990, Proceedings of the third International Symposium on Osteoporosis Copenhagen, Denmark 14-20 October 1990 Eds Claus Christiansen and Kirsten Overgaard, pp 1476-1478.          

S. M. Ott, G. C. Woodson, W. E. Huffer, Bone histomorphometric changes in women with postmenopausal osteoporosis treated with etidronate.  in Osteoporosis 1990, Proceedings of the Third International Symposium on Osteoporosis Copenhagen, Denmark 14-20 October 1990 Eds Claus Christiansen and Kirsten Overgaard, pp 1318-1322.

G. Woodson, Carlson LM, Treating osteoporosis: the etidronate option. Senior Patient 1991;3:8-15.

S.M. Ott, G. C. Woodson, W.E. Hufer, P.D. Miller, N.B. Watts, Effects of etidronate and phosphate on bone histomorphology in women with postmenopausal osteoporosis. Abstract # 561, J Bone Min Res August 1991 (supp 1) pp s224.

G. Woodson, Three effective treatments for osteoporosis.  Abstract presented at the Adult Bone and Mineral Working Group of the ASBMR, Tampa Sept 1993, J Bone Min Res 1993;s403.

Susan M. Ott, Grattan C. Woodson, William E. Huffer, Paul D. Miller, Nelson B. Watts, Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 1994;78:968-972.

Woodson,G., Phosphate depletion, osteomalacia, and aluminum intoxication due to antacid use in a patient with normal renal function. Oral presentation at the Adult Bone and Mineral Group of the ASBMR, Baltimore, MD September 1995. J Bone Min Res 1995:(supp 1):

Woodson,G., Adequate screening for axial osteoporosis with densitometry requires measurement of the hip and spine.  Poster presentation at the ASBMR, Baltimore, MD September 1995. J Bone Min Res 1995;(supp 1):     

M McClung, W Benson, M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P Miller, E Pavlov, S Silverman, G Woodson, K Kalkner, P Bekker,. Risedronate treatment of postmenopausal women with low bone mass: Preliminary Data. Osteoporosis Int 1996; (suppl 1):PTu 700

Woodson, GC.,.  An effectiveness study of etidronate therapy with and without estrogen. J Bone Min Res 1996;(supp 1):M651  

P Beeker, M McClung, W Benson, M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P Miller, E Pavlov, S Silverman, GC Woodson,  K Kalkner,  D Axelrod,. Risedronate is effective in increasing BMD in both early and late postmenopausal women with low bone mass.  J Bone Min Res 1997;(suppl 1): S474

McClung, M, W Benson, M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P Miller, E Pavlov, S Silverman, GC Woodson,  K Kalkner, P Bekker, D Axelrod,. Risedronate increases BMD at the hip and spine in postmenopausal women with low bone mass. J Bone Min Res 1997;(suppl 1): P269

Woodson, GC., The diagnosis of osteoporosis using the NHANES II Vs the Hologic normative data for the femoral neck., J Bone Min Res 1997;(suppl 1): S531

Woodson, GC., The supine lateral site is more sensitive for the diagnosis of osteoporosis than other axial DXA sites.  J Bone Min Res 1997;(suppl 1): F614

Woodson, GC., An interesting case of osteomalacia due to antacid use associated with stainable bone aluminum in a patient with normal renal function. Bone 1998; 22:6;695-985.

Silverman S, Genant HK, Kiel DP, Maricic MJ, Peacock M, Woodson GC., Salmon-Calcitonin nasal spray prevents fractures in established osteoporosis.  Additional interim fracture analysis of the “PROOF” study. 1998 Bone; 23(suppl 5)

Chestnut C, Maricic MJ, Silverman S, Woodson GC., Are bone mineral density and biomarkers good predictors of efficacy for prevention of osteoporotic fractures? – Salmon-calcitonin nasal spray and alendronate. 1998 Bone; 23(suppl 5)

Woodson GC., DXA T-score Concordance and Discordance between the PA Spine and the Total Hip Sites. (Oral presentation ASBMR 10-1-99, St Louis, MO) 1999, JBMR 14;suppl 1:#1027, S139

Rosen CJ, Bonnick SL, Miller PD, McClung MR, Wasnich RD, Weiss SR, Woodson GC, Schnitzer TJ, Lenihan JP, Ross RP, Wang L, Smith ME, Gormley GJ, Melton, ME., Treatment of osteoporosis in postmenopausal women: alendronate vs intranasal spray calcitonin (effect on bone markers). 1999, JBMR 14;suppl 1:# SA 364, S399.

Rosen CJ, Bonnick SL, Miller PD, McClung MR, Wasnich RD, Weiss SR, Woodson GC, Schnitzer TJ, Lenihan JP, Ross RP, Wang L, Smith ME, Gormley GJ, Melton, ME., ., Treatment of osteoporosis in postmenopausal women: alendronate vs intranasal spray calcitonin (effect on BMD) 1999, JBMR 14;suppl 1:# S365, S400.

Fogelman I, Moreland L, Woodson GC, Mellstrom D, Boling E, Riskin W, Strauss D, Stevens K, Manhart M., Gastrointestinal side effects and endoscopic findinings similar between risedronate and placebo-treated patients.  2000 Osteoprosis Int (Suppl 2)1179;459

Woodson GC., Once Weekly Risedronate Therapy. 2000, Osteoporosis Int (suppl 2) s204, 550

Hooper M, Hanley D, Eastell R, Boling B, Ribot C, Woodson GC, Barton I., Sustained Effect of Risedronate in the Prevention of the First Vertebral Fracture in Women.   2000, J Bone Min Res (suppl 1) SU400, s428

Josse R, Fogelman I, Woodson GC, Boling E, Stevens K,. Gastrointestinal side effects and endoscopic findings similar between risedronate and placebo treated patients.  2000, Presented at the Endocrine Society Meeting, Toronto, CA on 6-12-2000

Woodson, GC., T-score concordance and discordance between the hip and spine measurement sites.  J. Clinical Densitometry, 2000;3:319-324.

Miller P, Woodson GC, Licata AA, Ettinger MP, Mako B, Smith ME, Wang L, Yates J, Melton ME, Pamisano JJ,. Rechallange of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. 2000, Clin Ther 22;1433-1422.

Woodson GC Risk Factors for Osteoporosis in Postmenopausal African American Women 2003, J Bone and Mineral Res., Supp 1

Shergy W, Greenwald W, Woodson G, Chen P, Misurski D, Wagman R.  Teriparatide Demonstrates Early Effects in Postmenopausal Women with Osteoporosis  Abstract presentation at the American Association of Clinical Endocrinologist Meeting (April 28-May 2, 2004 Boston, Massachusetts) and the Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis Meeting (May 24-25, 2004 Bethesda, Maryland).